Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy

Nephrology Dialysis Transplantation

Volumn 26, Issue 3, 2011, Pages 970-976

  Grzegorzewska, Alicja E ^a   Kaczmarek Leki, Vanessa ^b   Młot Michalska, Monika ^a   Niepolski, Leszek ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b International Dialysis Center Ostrów Wielkopolski   (Poland)

^c B Braun Avitum Nowy Tomyśl ^*  (Poland)

Author keywords

anti HBc; anti HBs; haemodialysis; renal replacement therapy vintage; seroconversion

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; VIRUS RNA;

ADULT; AGE; ANTIBODY RESPONSE; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GENDER; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTENSION; IMMUNOASSAY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEROCONVERSION; TREATMENT DURATION; VACCINATION;

DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; RISK FACTORS; SURVIVAL RATE; VIRION;

EID: 79952165195     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq499     Document Type: Article

References (48)

1. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999;33:356-360 (Pubitemid 29072240)
2. Finelli L, Miller JT, Tokars JI et al. National surveillance of dialysisassociated diseases in the United States, 2002. Semin Dial 2005;18:52-61 (Pubitemid 40348277)
3. Rutkowski B, Lichodziejewska-Niemierko M, Grenda R et al. Report on the Renal Replacement Therapy in Poland-2007. Drukonsul, Gdansk 2009;30-34
4. Grzegorzewska AE, Kurzawska-Firlej D, Swiderski A et al. Infections with hepatitis B virus in hemodialysis units of Wielkopolska [article in Polish]. Przegl Epidemiol 2008;62:29-37
5. Yen-Xuan NT, Dieu-Hien PT, Nga CN et al. Clinical and virological features of acute HBV-related hepatitis in southern Vietnam. Ann Hepatol 2006;5:92-96
6. Thanachartwet V, Phumratanaprapin W, Desakorn V et al. Viral hepatitis infections among dialysis patients: Thailand registry report. Nephrology (Carlton) 2007;12:399-405 (Pubitemid 47075423)
7. Ribot S, Rothstein M, Goldblat M et al. Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. Arch Intern Med 1979;139:178-180 (Pubitemid 10132266)
8. Harnett JD, Parfrey PS, Kennedy M et al. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988;11:210-213 (Pubitemid 18086760)
9. Oesterreicher C, Hammer J, Koch U et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int 1995;48:1967-1971
10. Minuk GY, Sun DF, Greenberg R et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004;40:1072-1077 (Pubitemid 39425562)
11. Fabrizi F, Messa PG, Lunghi G et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005;21:1341-1347 (Pubitemid 40813680)
12. Moreira RC, Deguti MM, Lemos MF et al. HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up. Mem Inst Oswaldo Cruz 2010;105:107-108
13. Vladutiu DS, Cosa A, Neamtu A et al. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat 2000;7:313-319
14. Grzegorzewska AE, Kurzawska-Firlej D, Ratajewski W et al. Antibodies to core antigen of hepatitis B virus in patients on renal replacement therapy: association with demographic, clinical and laboratory data. Nephron Clin Pract 2010;114:194-203
15. European Best Practice Guidelines. Prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant 2002;17:78-87
16. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep 2001;50:1029-1032
17. Cendoroglo Neto M, Draibe SA, Silva AE et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995;10:240-246
18. Johnson DW, Dent H, Yao Q et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009;24:1598-1603
19. Shakhgil'dian IV, Khukhlovich PA, Savin EA et al. Risk of infection with hepatitis B and C viruses of medical workers, patients in the hemodialysis ward, and vaccine prophylaxis of hepatitis B infection in these populations [article in Russian]. Vopr Virusol 1994;39:226-229
20. Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:2335-2342 (Pubitemid 38670020)
21. Ferreira RC, Rodrigues FP, Teles SA et al. Prevalence of hepatitis B virus and risk factors in Brazilian non-injecting drug users. J Med Virol 2009;81:602-609
22. Jilg W, Sieger E, Zachoval R et al. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995;23:14-20
23. Hayashi J, Nakashima K, Kajiyama W et al. Prevalence of antibody to hepatitis C virus in hemodialysis patients. Am J Epidemiol 1991;134:651-657
24. Steketee RW, Ziarnik ME, Davis JP. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. Am J Epidemiol 1988;127:772-782
25. Fabrizi F, Di Filippo S, Marcelli D et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 1996;72:536-543
26. Sorkhi H, Roushan MR, Al Hashemi GH et al. Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. East Mediterr Health J 2008;14:798-803
27. DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003;42:1184-1192 (Pubitemid 37486762)
28. Tokars JI, Miller ER, Alter MJ et al. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998;44:98-107 (Pubitemid 28084068)
29. Bruguera M, Cremades M, Mayor A et al. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Post grad Med J 1987;63:155-158 (Pubitemid 17094420)
30. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996;73:417-420 (Pubitemid 26229695)
31. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol 2000;20:1-11 (Pubitemid 30047863)
32. Trepo CG, Prince AM. Absence of complete homologous immunity in hepatitis B infection after massive exposure. Ann Intern Med 1976;85:427-430
33. Hoofnagle JH, Gerety RJ, Smallwood LA et al. Subtyping of hepatitis B surface antigen and antibody by radioimmunoassay. Gastroenterology 1977;72:290-296 (Pubitemid 8028399)
34. Koziol DE, Alter HJ, Kirchner JP et al. The development of HBsAgpositive hepatitis despite the previous existence of antibody to HBsAg. J Immunol 1976;117:2260-2262 (Pubitemid 8009026)
35. Waters JA, Kennedy M, Voet P et al. Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992;90:2543-2547 (Pubitemid 23010076)
36. Chabaud M, Depril N, Le Cann P et al. Detection of hepatitis B virus DNA by polymerase chain reaction in vaccinated and non-vaccinated Senegalese children. Arch Virol Suppl 1993;8:123-131
37. Lombardi M, Pizzarelli F, Righi M et al. Hepatitis B vaccination in dialysis patients and nutritional status. Nephron 1992;61:266-268
38. Su WJ, Ho MC, Ni YH et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203-208
39. Snydman DR, Bryan JA, London WT et al. Transmission of hepatitis B associated with hemodialysis: role of malfunction (blond leaks) in dialysis machines. J Infect Dis 1976;134:562-570 (Pubitemid 8015073)
40. Roberts RC, Lane C, Hatfield P et al. All anti-HBc-positive, HBsAg-negative dialysis patients on the transplant waiting list should be regarded as at risk of hepatitis B reactivation post-renal transplantation- report of three cases from a single centre. Nephrol Dial Transplant 2006;21:3316-3319 (Pubitemid 44567114)
41. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539 (Pubitemid 46374607)
42. Cabrerizo M, Bartolomé J, De Sequera P et al. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997;8:1443-1447 (Pubitemid 27491236)
43. Blanpain C, Knoop C, Delforge ML et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation 1998;66:883-886 (Pubitemid 28487462)
44. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg (-), HBcAb (+), HBIgM (-) organ donors. Transplantation 1995;59:230-234
45. French AL, Lin MY, Evans CT et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis 2009;49:148-154
46. Hassan MM, Li D, El-Deeb AS et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008;26:4557-4562
47. Adachi S, Shibuya A, Miura y et al. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 2008;43:849-856 (Pubitemid 351918521)
48. Kim MJ, Kwon OS, Chung NS et al. The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis [article in Korean]. Korean J Hepatol 2008;14:67-76